Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000632832 | SCV000754028 | pathogenic | Peutz-Jeghers syndrome | 2017-09-18 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Arg86*) in the STK11 gene. It is expected to result in an absent or disrupted protein product. This variant is not present in population databases (ExAC no frequency). This variant has been reported in individuals affected with Peutz–Jeghers syndrome (PMID: 9887330, 26979979). Loss-of-function variants in STK11 are known to be pathogenic (PMID: 15188174, 16287113). For these reasons, this variant has been classified as Pathogenic. |
Baylor Genetics | RCV003459509 | SCV004205605 | pathogenic | Melanoma, cutaneous malignant, susceptibility to, 1 | 2022-08-10 | criteria provided, single submitter | clinical testing | |
Myriad Genetics, |
RCV000632832 | SCV004933525 | pathogenic | Peutz-Jeghers syndrome | 2024-02-09 | criteria provided, single submitter | clinical testing | This variant is considered pathogenic. This variant creates a termination codon and is predicted to result in premature protein truncation. |
Department of Clinical Genetics, |
RCV000632832 | SCV005685040 | pathogenic | Peutz-Jeghers syndrome | 2025-01-10 | criteria provided, single submitter | clinical testing | The following ACMG criteria was used: PVS1; PM2_SUP; PS4_SUP |